�������

My research background is multidisciplinary, spanning psychiatry, biomedical engineering, and neuroimaging. Over the past five years, I have primarily focused on investigating the therapeutic potential of psychedelics and other psychoactive compounds – an evolving field at the intersection of clinical neuroscience, pharmacology, and mental health treatment.

At the Center for Psychedelic Medicine at ������� Langone, I have been actively involved in clinical trials investigating psilocybin as a treatment for depression, alcohol use disorder, and cancer-related psychiatric distress. Through this work, I have gained extensive experience in clinical trial design, data analysis, and psychedelic-assisted therapy, contributing to the growing body of evidence supporting the safe and effective use of psychedelics in psychiatry.

More recently, my research has focused on utilizing advanced neuroimaging techniques, including functional magnetic resonance imaging (fMRI) and functional near-infrared spectroscopy (fNIRS), to better understand the pharmacological and neural mechanisms of psychedelic compounds. By integrating neuroimaging data with computational modeling and machine learning, I aim to:

1. Develop objective, brain-based biomarkers for psychiatric conditions

2. Identify key mechanisms of action of psychedelics and other psychoactive drugs

3. Establish dose-response relationships to quantitively link neuropharmacology with clinical outcomes

Ultimately, my goal is to bridge the gap between basic neuroscience and clinical applications, accelerating the translation of psychedelic research from the lab to real-world psychiatric treatment. By leveraging neuroimaging and computational approaches, I hope to optimize psychedelic therapies for personalized, precision-based mental health care.